版本:
中国

BRIEF-Atara Biotherapeutics reports positive interim early-stage data on multiple sclerosis drug

April 20 Atara Biotherapeutics Inc-

* Atara Bio announces positive interim results from ongoing phase 1 trial of the autologous version of ata188 in patients with primary and secondary progressive multiple sclerosis (ms) at the american academy of neurology (aan) annual meeting 2017

* Atara Biotherapeutics Inc - look forward to further development of autologous ata188 for patients with ms

* Atara Biotherapeutics Inc - expected initiation of both phase 1 allogeneic ata188 trial as well as our phase 3 trials of ata129 in second half of year.

* Atara Biotherapeutics Inc - no patient in trial experienced progression of disability; there was no worsening in edss Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐